Very recent onset arthritis: The value of initial rheumatologist evaluation and anti-cyclic citrullinated peptide antibodies in the diagnosis of rheumatoid arthritis

Clinical Rheumatology

Volumn 28, Issue 10, 2009, Pages 1135-1139

  Rojas Serrano, Jorge ^a   Burgos Vargas, Rubén ^b   Lino Pérez, Leticia ^b   García García, Conrado ^b   Moctezuma, Francisco ^b   Vázquez Mellado, Janitzia ^b  

^a INSTITUTO NACIONAL DE ENFERMEDADES RESPIRATORIAS   (Mexico)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

Anti cyclic citrullinated peptide antibodies; Rheumatoid arthritis; Very early arthritis

Indexed keywords

CYCLIC CITRULLINATED PEPTIDE ANTIBODY; DISEASE MODIFYING ANTIRHEUMATIC DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; DISEASE DURATION; EARLY DIAGNOSIS; FEMALE; FOLLOW UP; HUMAN; JOINT SWELLING; MAJOR CLINICAL STUDY; MALE; MORNING STIFFNESS; POLYARTHRITIS; PREDICTION; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SELF REPORT; SENSITIVITY AND SPECIFICITY;

ADULT; ANTIBODIES, ANTI-IDIOTYPIC; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; COHORT STUDIES; DISABILITY EVALUATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; JOINTS; MALE; MIDDLE AGED; PEPTIDES, CYCLIC; PREDICTIVE VALUE OF TESTS; REGRESSION ANALYSIS; SENSITIVITY AND SPECIFICITY;

EID: 69949168726     PISSN: 07703198     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10067-009-1206-z     Document Type: Article

References (17)

1. Gordon DA, Hastings DE (2003) Clinical features of rheumatoid arthritis. In: Hochberg MC, Silman AJ, Smolen JS, Weinblat ME, Weisman MH (eds) Rheumatology, 3rd edn. Mosby, Edinburgh, pp 765-780
2. Van der Heijde D, van Riel PL, Nuver-Zwart HH, Gribnau FW, van de Putte LBA (1989) Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis. Lancet 1:1036-1038
3. Egsmose C, Lund B, Borg G, Pettersson H, Berg E, Brodin U et al (1995) Patients with rheumatoid arthritis benefit from early 2nd line therapy: 5-year followup of a prospective double blind placebo controlled study. J Rheumatol 22:2208-2213
4. Abu-Shakra M, Toker R, Flusser D, Flusser G, Friger M, Sukenik S et al (1998) Clinical and radiographic outcomes of rheumatoid arthritis patients not treated with disease modifying drugs. Arthritis Rheum 41:1190-1195
5. Krause D, Schleusser B, Herborn G, Rau R (2000) Response to methotrexate treatment is associated with reduced mortality in patients with severe rheumatoid arthritis. Arthritis Rheum 43:14-21
6. Choi HK, Hernán MA, Seeger JD, Robins JM, Wolfe F (2002) Methrotexate and mortality in patients with rheumatoid arthritis: A prospective study. Lancet 359:1173-1177
7. Harrison BJ, Symmons DPM, Barret EM, Silman AJ (1998) The performance of the 1987 ARA classification criteria for rheumatoid arthritis in a population based cohort of patients with early inflammatory polyarthritis. J Rheumatol 25:2324-2330
8. Van der Helm-van Mil AHM, Saskia LC, von Dongen H, Breedveld FC, Toes REM, Huizinga TWJ (2007) A prediction rule for disease outcome in patients with recent-onset undifferentiated arthritis. Arthritis Rheum 56:433-440
9. Visser H, le Cessie S, Vos K, Breedveld FC, Hazes JMW (2002) How to diagnose rheumatoid arthritis early. A prediction model for persistent (erosive) arthritis. Arthritis Rheum 46:357-365
10. Machold KP, Stamm TA, Eberl GJM, Nell VKP, Dunky A, Uffman M (2002) Very recent onset arthritis-clinical, laboratory, and radiological findings during the first year of disease. J Rheumatol 29:2278-2287
11. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315-324
12. Harrison BJ, Symmons DPM, Brennan P, Barret EM, Silman AJ (1996) Natural remission in inflammatory polyarthritis: Issues of definition and prediction. Br J Rheumatol 35:1096-1100
13. Tan EM, Cohen AS, Fries JR et al (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271-1277
14. O'Dell JR (2004) Therapeutic strategies for rheumatoid arthritis. N Engl J Med 350:2591-2602
15. Schellekens GA, Visser H, de Jong BAW, van den Hoogen FHJ, Hazes JMW, Breedveld FC et al (2000) The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 43:155-163
16. Nielen MMJ, Van Schaardenburg D, Reesink HW, Van de Stadt RJ, Van der Horst-Bruinsma IE, De Koning MHMT et al (2004) Specific autoantibodies precede the symptoms of rheumatoid arthritis. A study of serial measurements in blood donors. Arthritis Rheum 50:380-386
17. Rantapää-Dahlqvist S, De Jong BAW, Berglin E, Hallmans G, Wadell G, Stenlund H et al (2003) Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 48:2741-2749